Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nadia Hindi
Observed names:
N. Hindi Muñiz,
Nadia H. Muñiz,
Nadia Hindi Muñiz
Institution:
Hospital Universitario Fundación Jiménez Díaz
Observed institutions:
Hospital Universitario La Paz,
Hospital Universitario Fundación Jiménez Díaz,
Instituto de Investigación Sanitaria Fundación Jiménez Díaz,
Hospital Universitario General de Villalba,
Universidad Autónoma de Madrid
ORCID:
0000-0002-5864-762X
Observed ORCID:
0000-0002-5864-762X
OpenAlex ID:
A5137578470
Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study
2022
·
Fabio Conforti
, Alessandro Gronchi
, et al.
·
European Journal of Cancer
·
21
Cáncer de colon hereditario
2011
·
Nadia Hindi Muñiz
, Ángela Lamarca Lete
, et al.
·
Medicina Clínica
·
6
First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas
2026
·
José Antonio Gonzalez
, Ana Sebio
, et al.
·
Annals of Surgical Oncology
·
1
Results of a survey on the treatment of adolescents and young adult (AYA) sarcoma patients in Spain at present time
2022
·
Cristina Mata Fernández
, Nacho Gutierrez Carrasco
, et al.
·
Clinical & Translational Oncology
·
1
Surgical Management and Therapeutic Strategy of Uterine Sarcoma According to Histological Subtype and Staging: Updated Review and Recommendations
2026
·
Francisco Cristóbal Muñoz-Casares
, José Gómez-Barbadillo
, et al.
·
Cancers
Supplementary Table S3 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Table S1 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Table S2 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Data from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Figure S1 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Figure S2 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Data from Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma
2026
·
David S. Moura
, Jesus Lopez-Marti
, et al.
115P Impact of clinical and treatment factors on trabectedin toxicity in soft tissue sarcomas
2025
·
C. Santomá Saladich
, C. López Jiménez
, et al.
·
ESMO Open
PDF
1926P Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients: Results from the SYNERGIAS study - A Spanish group for research in sarcoma (GEIS) phase II study
2023
·
J. Martin-Broto
, K. Kopeckova
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
14
Citation count:
29
H-index:
2
I10-index:
1
Year
Topic
Type